FDMT FY 2023 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M+562.3% YoY

Gross Profit

-$76M-368.5% margin

Operating Income

-$113M-544.6% margin

Net Income

-$101M-486.6% margin

EPS (Diluted)

$-2.58

Cash Flow

Operating Cash Flow

-$76M

Free Cash Flow

-$79M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$340M

Total Liabilities

$32M

Stockholders' Equity

$308M

Cash & Equivalents

$249M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$3M	+562.3%
Gross Profit	-$76M	-$77M	+1.0%
Operating Income	-$113M	-$110M	-2.6%
Net Income	-$101M	-$107M	+6.2%